Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
- PMID: 40129218
- DOI: 10.1093/jac/dkaf095
Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
Abstract
Background: Enterococcus gallinarum and Enterococcus casseliflavus are increasingly identified as causes of healthcare-associated infections. Although hepatobiliary infection and catheter-related bloodstream infection predominate, endovascular infection can also occur. The optimal treatment of these infections is unknown.
Objectives: To determine the in vitro activity of ampicillin, gentamicin and ceftriaxone against clinical isolates of E. gallinarum and E. casseliflavus.
Methods: Bloodstream isolates of E. gallinarum (n = 10) and E. casseliflavus (n = 8) were collected from unique patients between 2008 and 2022 at one institution. The activity of ampicillin was tested alone and combined with gentamicin and ceftriaxone by the time-kill method.
Results: All isolates were susceptible to ampicillin and none had gentamicin MIC > 128 mg/L. At concentrations of 0.25 × MIC, ampicillin plus gentamicin was synergistic against 5 of 10 E. gallinarum and all 8 E. casseliflavus, and was bactericidal against 12 of the 18 strains. In contrast, ampicillin plus ceftriaxone was synergistic and bactericidal against only 1 of 10 E. gallinarum and 0 of 8 E. casseliflavus. When the concentration of ampicillin was increased to 10 mg/L, above the MIC for all strains, the combination of ampicillin plus gentamicin was bactericidal against all isolates.
Conclusions: These data suggest that the ampicillin plus gentamicin combination is frequently synergistic and typically bactericidal and may be the preferred treatment option for endovascular infection caused by E. gallinarum or E. casseliflavus. In contrast to the findings for Enterococcus faecalis, ampicillin plus ceftriaxone is generally not synergistic or bactericidal and thus may not be as effective.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infection.Sci Rep. 2025 Jan 28;15(1):3519. doi: 10.1038/s41598-025-87512-8. Sci Rep. 2025. PMID: 39875507 Free PMC article.
-
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization.J Antimicrob Chemother. 2025 Sep 3;80(9):2513-2523. doi: 10.1093/jac/dkaf260. J Antimicrob Chemother. 2025. PMID: 40693491
-
Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies.Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):17-31. doi: 10.1007/s10096-023-04704-8. Epub 2023 Nov 17. Eur J Clin Microbiol Infect Dis. 2024. PMID: 37975976
-
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates.J Antimicrob Chemother. 2025 Sep 3;80(9):2524-2529. doi: 10.1093/jac/dkaf262. J Antimicrob Chemother. 2025. PMID: 40720087
-
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.Health Technol Assess. 2021 Oct;25(59):1-224. doi: 10.3310/hta25590. Health Technol Assess. 2021. PMID: 34668482
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical